Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT04421846Recruiting
Studying the causes of severe seizures and immune brain swelling
This study looks at what causes severe seizure episodes (“status epilepticus”) and a related immune condition that affects the brain (“dysimmune encephalitis”). The goal is to better understand the disease process, which may guide future care.
ParisAges 2 years+ - NCT04438525Recruiting
BAT test to replace sting challenge in venom allergy care
This study looks at whether a BAT (a blood test) can stand in for sting/venom “challenges” for people already receiving venom immunotherapy. If it works, it could help patients avoid more risky or uncomfortable challenge procedures while still checking whether treatment is working.
GrazAges 18–70 - NCT04391335Recruiting
Breathing tests to spot lung scarring after stem cell transplant
This study checks new ways to measure breathing in children who had a stem cell transplant to better detect a lung condition called bronchiolitis obliterans syndrome. If you join, you’ll do breathing and imaging tests, and researchers will look for patterns that may help with diagnosis.
Toronto, OntarioAges 6–18 - NCT04476563Recruiting
Study liver injury from checkpoint cancer immunotherapy
This study looks at why some people develop liver inflammation after checkpoint inhibitor cancer treatment, called checkpoint inhibitor–induced liver injury (ChILI). It compares people with ChILI to similar cancer patients who are starting the same type of immunotherapy, to better understand and track these liver injury events.
NottinghamAges 18 years+ - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT04459689Recruiting
COVID-19 study for people with primary immune deficiencies
This study looks at COVID-19 experiences in people who have a primary immune deficiency (a long-term immune problem) and who have had COVID-19. It may help researchers better understand how COVID-19 affects people with these conditions.
ParisAges birth+ - NCT04460235RecruitingPhase 4
Compare two pneumococcal vaccines in adults treated for lymphoma
This trial compares two vaccination plans to see which one works better for preventing pneumococcal infections after lymphoma chemotherapy. You may be randomly assigned to one of the vaccine strategies, and the study checks your immune response.
AngersAges 18 years+ - NCT04469842RecruitingEarly Phase 1
Long-acting tacrolimus after lung transplant
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
Nashville, TennesseeAges 18 years+ - NCT04419584RecruitingPhase 2/Phase 3
Modified Qing-Ying decoction for children with eczema
This trial tests a traditional Chinese herbal formula (Modified Qing-Ying Decoction) for children ages 4 to 17 with moderate-to-severe eczema (atopic dermatitis). The study aims to see if this herbal treatment can improve skin dryness, redness, and itching, especially for those with dry, scaly patches.
Hong KongAges 4–17 - NCT04375800RecruitingPhase 2
Doravirine for children with HIV infection and stable treatment
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Aurora, ColoradoAges 4 weeks–11 years - NCT04456816RecruitingPhase 2
Drug test for IgA? No—anti-PLA2R positive immune kidney disease
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
AarhusAges 18–85 - NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT04422912RecruitingPhase 1/Phase 2
Cell therapy trial for active pemphigus vulgaris
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
Redwood City, CaliforniaAges 18 years+ - NCT04414475RecruitingPhase 2
Selinexor plus low-dose steroid for hard-to-treat myeloma
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Pátrai, AchaiaAges 18 years+ - NCT04466059Recruiting
AI tool for leukemia diagnosis using blood or marrow samples
This study tests whether an AI (computer system) can help improve leukemia and related blood cancer diagnoses. You may be able to help if your doctor is already evaluating you for a possible blood disorder and your sample is high enough quality for testing.
Munich, BavariaAges 18 years+ - NCT04180085RecruitingPhase 2
Belatacept to protect kidneys in heart transplant patients
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
BordeauxAges 18 years+ - NCT04304820RecruitingPhase 2
Testing early oral cyclosporine and eltrombopag for severe anemia
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
Bethesda, MarylandAges 3–99 - NCT04303117RecruitingPhase 1/Phase 2
Test drug PDS01ADC alone and with immunotherapy for Kaposi sarcoma
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Bethesda, MarylandAges 18–99 - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT04301076RecruitingPhase 1
Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Atlanta, GeorgiaAges 18 years+ - NCT04322383RecruitingPhase 2
Binimetinib for relapsed or refractory hairy cell leukemia
This trial tests a drug called binimetinib in people with a type of leukemia that has come back or not responded to treatment. It is for those whose cancer cells do not have a BRAF mutation.
Bethesda, MarylandAges 18 years+ - NCT04329728RecruitingPhase 1/Phase 2
Study drug for relapsed or refractory lymphoid cancers
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Duarte, CaliforniaAges 12–95 - NCT04290000Recruiting
Share samples after CAR-T treatment at Montpellier hospital
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
MontpellierAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.